RFID Smart Cabinets Market to Register 12% CAGR till 2020

The global RFID Smart Cabinets Market is expected to grow at a nearly 12% CAGR during the forecast period (2012 to 2020). The industry is poised to reach around USD 785 million by 2020. In healthcare, RFID (radio-frequency identification) is applied widely in equipment tracking and in record maintenance. Cost cutting measures adopted by healthcare institutions for effective inventory management drive demand for RFID smart cabinets. These cabinets are made of two components, namely, RFID console and a steel/aluminum cabinet. The cabinet is used for maintaining databases, like identity of the person or department that accessed it recently and the date of last usage. RFID console is an electronic part that helps keep a track on cabinet supplies. Surging demand for RFID cabinets for inventory management and technological advancements are expected to positively impact the global market throughout the forecast period.

The worldwide RFID Smart Cabinets Market is segmented into geographies, namely Latin America, North America, Asia Pacific, Europe, and Rest of the World. Most healthcare institutions in North America have begun using RFID cabinets for enhanced productivity and minimal errors. The region is propelled by huge product demand from the U.S. Sophisticated healthcare infrastructure and steady technological developments are two key factors that drive the North America market. This region may continue leading the global industry till 2020.

Browse Details of Report @ https://www.hexaresearch.com/research-report/rfid-smart-cabinets-industry

In the U.K. and Germany, huge funds are injected into the healthcare sectors by both governmental organizations and NGOs. Germany dominates the Europe RFID cabinets market owing to high R&D investments in RFID applications. With focus on RFID technologies, the government of Germany had invested around USD 260 million in the year 2007. Furthermore, the country declared that technological developments fuel applications of RFID technologies not only in the healthcare sector but also in its telecommunications industry. The need for effective inventory management strategies and the prevention of pilferage of assets & inventories can fuel the global industry during the forecast period.

Owing to surging demand from India and China, Asia Pacific is expected to be a rapidly growing region from 2012 to 2020. Furthermore, technological developments and improvements in healthcare infrastructure in China and India could effectively contribute to regional progress. Execution of the 12 year plan in China may lead manufacturers to invest robustly in the region. Favorable governmental regulations, the expanding telecommunications sector, and widespread awareness among patients are factors that drive the RFID industry in India. Proliferation of retail stores selling products with RFID tags can positively impact the overall industry during the forecast period.

Prominent industry participants are Tagsys RFID Group; Stanley Innerspace; LogTag; Mobile Aspects Inc.; and Terson Solutions Inc. among others. The global RFID smart cabinets market is a highly fragmented one with a large pool of suppliers and a host of domestic manufacturers in China. Mergers and acquisitions are key business expansion strategies adopted by several companies. In February 2016, Nordic ID launched the Nordic ID AR52 area reader. It is a fixed reader that is equipped with sixteen external antenna ports. It is the centre point for connecting the antennas that can be adjusted and controlled individually.

Browse Related Category Report @ https://www.hexaresearch.com/research-category/medical-devices-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com

Electromedical and X-ray Equipment Market Size and Share Report, 2024

22 March 2019, X-beam is a kind of electromagnetic ionizing radiation with applications in a broadened scope of businesses. In therapeutic industry, X-beam gadgets constitute the biggest offer of the symptomatic imaging market. The maturing of the world's population and the rising occurrence of growth, coronary illness, and different conditions is driving the demand for Electromedical And X-Ray Equipment Market for cancer, heart disease, and X-rat gadgets. Interest is driven by mechanical progressions, demographics (the maturing US populace drives the requirement for medicinal items), and the necessities of the human services industry. The profitability of individual organizations relies on upon operations and viable advertising. Vast organizations appreciate economies of scale in examination, assembling, advertising, and conveyance. Littler organizations can contend adequately by creating inventive advancements or claim to fame items for corner markets, for example, growth treatment device.

Accessibility of substantial number of players in the business sector has led to a nonstop evolvement of cutting edge advances to build image quality. Advanced imaging procedures keep on evolving with enhancements in picture quality, measurement lessening systems, and efficiencies in work process. The X-ray gadgets innovation has moved from simple imaging to advance. X-rays show numerous applications in the diagnostic as well as therapeutic areas of cancer, cardiovascular and mid-section illnesses to give some examples. Fast advances in radiology that have happened in the previous couple of decades have made ready for the extension of the medicinal imaging hardware market. Imaging gadgets, for example, magnetic resonance imaging (MRI), computed tomography (CT or CAT), and ultrasound have permitted further choices for treatment direction with low dismalness. This has helped doctors to evaluate patients without surgical mediation and along these lines enhance the patient results and personal satisfaction

Browse Details of Report @ https://www.hexaresearch.com/research-report/electromedical-x-ray-equipment-market

X-ray imaging gadgets constituted the key fragmenst in the worldwide medical imaging equipment market. The key driving forces for the development of this segment includes expanding occurrence of scatters and simple accessibility and adequacy of x-ray gadgets. Rising occurrence of cardiovascular, respiratory, oral, gastrointestinal, and genitourinary scatters are boosting dependence on a few propelled x-beam indicative gadgets all around. The WHO gauges that around 60% to 90% of school kids and 80% to 90% grown-ups (matured 19 to 34 years) experience the ill effects of dental cavities. In addition, the worldwide rate of oral growth ranges between 1-10 cases for every 100,000 people. These two variables, combined with an expansive patient pool of patients experiencing dental pits, is expected to boost the industry growth. Among the x-ray gadgets market, stationary gadgets overwhelmed the business sector by ideals of being routinely utilized imaging gadgets. These are likewise a more financially savvy choice contrasted with compact x-beam hardware gadgets. Stationary gadgets are for the most part favored in the underserved markets of Asia and Africa.

Based on product type, the Electromedical and X-ray Equipment Market is segmented into Digital Radiography (DR), Computed Radiography (CR) and retrofit radiography system. Electro-medical equipment includes a variety of powered devices, such as pacemakers, patient-monitoring systems, MRI machines, diagnostic imaging equipment (including informatics equipment), and ultrasonic scanning devices.

Established markets such as the US, Western Europe, and Japan are top sales regions for the industry. Developing nations such as Brazil, Russia, India, and China are targeted by companies in the industry for growth.

Major US companies include Medtronic,Hologic, Varian Medical Systems,, St Jude Medical and ZollMedical, as well as  General Electric. Outside the US, major companies includeSonova (Switzerland), St Jude Medical,, St Jude Medical., Bracco Imaging S.p.A, , Agfa-Gevaert N.V ,Canon, Inc., Fujifilm Holdings Corporation,,Agfa-Gevaert N.V, Hologic, Inc., Hitachi Medical Corporation, Konica Minolta, Inc., Shimadzu Corporation,, Agfa-Gevaert N.V., Philips Healthcare, , Agfa-Gevaert N.V , Thales group,, Agfa-Gevaert N.V, Varian Medical Systems, Inc., , Agfa-Gevaert N.V  and Ziehm Imaging, Inc.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-imaging-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com

Orthobiologics Market Size, Share, Trends and Competition, 2025

13 March 2019, The global Orthobiologics Market is expected to witness strong growth in the years to come due to rising prevalence of musculoskeletal and orthopedic illnesses across the world. Increasing road accidents and sports injuries are likely to increase the product demand in the coming years. In addition, growing geriatric population is a key driving factor in the market as they are more vulnerable to spinal and other orthopedic disorders. This has, in turn, increased the number of orthopedic procedures.

Advancements in implant techniques and rising demand for biological solutions over mechanical solutions are likely to create opportunities for the market. Technological advancements in biomaterials, which are utilized in the production of orthobiologics, are anticipated to support market growth. Such advancements include development of recombinant biologic agents, modifications in graft designs, stem cell therapy, and cultured tissue scaffolds. These innovations are likely to provide benefits, such as smaller incisions, improved biocompatibility, and reduced procedure time. Reduction in post-operative complications using these innovative solutions is expected to boost market growth in the years to come. Furthermore, increasing prevalence of obesity and arthritis, especially in developed countries is expected to boost market growth. This has, in turn, increased the demand for minimally invasive surgeries that generally include bone grafting and growth factor treatments. Orthobiologic therapy is one of the key components of regenerative medicine that are used to treat musculoskeletal diseases, including degenerative osteoarthritis. It is one of the important treatment options for early osteoarthritis (OA) of the knee.

However, strict regulatory framework regarding approval of orthobiologics and high cost of these products are anticipated to challenge the market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/orthobiologics-market

Orthobiologics include a wide range of products, such as bone matrix (DBM), allograft, synthetic bone substitutes, bone morphogenetic protein (BMP), stem cell therapy, and viscosupplementation. Viscosupplementation holds a prominent share in the market due to its high adoption in diseases, such as hip degenerative joint disease and osteoarthritis. Benefits, including fewer side effects, pain reduction, better knee movement, and less-invasive nature, are likely to boost the product’s demand. Moreover, increasing popularity of minimally invasive surgeries is anticipated to boost the segment’s growth in the coming years. Orthobiologics are extensively used in applications, such as spinal fusion, trauma repair, and reconstructive surgery. Spinal fusion is a leading application in the market due to increasing use of demineralized bone matrices, bone morphogenetic proteins, and autografts and allografts in spinal fusion surgeries. This could be attributed to its ability to speed up the bone healing process and offer high bone stability, facilitating long-term improvement of spinal disorders. It also offers fast stimulation of cells to enable bone formation and avoids hospital stays and repetitive visits. Key end users of orthobiologics include hospitals and orthopedic clinics. Hospital occupies a larger share in the market than clinics due to increasing use of orthobiological products in various spinal and reconstructive surgeries conducted in hospitals.

North America is one of the leading regional markets due to presence of key players involved in undertaking new product development strategies. In addition, availability of better compensation policies for soft tissue healing and fusion improvement products is boosting regional market growth.

Asia Pacific is projected to witness strong growth in the years to come owing to rising healthcare expenditure and improving economic conditions. Additionally, increasing awareness regarding availability of these products among physicians is likely to increase their sales. Frequent product launch and improvement in healthcare infrastructure are also projected to offer remunerative gains in the years to come.

Some of the key players operating in the orthobiologics market are DePuy Synthes, Inc.; Medtronic; Stryker Corporation; Genzyme; and Smith & Nephew plc. Players are increasingly investing in R&D activities and taking up strategies, such as mergers and acquisitions, to gain a competitive edge in the market. Moreover, increasing collaborations between biotechnology and medical device companies for the development of effective orthobiologics is expected to support market growth.

For instance, BONESUPPORT, a prominent company in orthobiologics for the management of bone voids, announced that it has started selling CERAMENT BVF through its own US distributor network. Similarly, Cesca Therapeutics Inc. announced that its subsidiary named ThermoGenesis, introduced its PXP System. The system offers fast processing of autologous bone marrow cells in the point-of-care (POC) setting.

Browse Related Category Market Reports@ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Kidney Cancer Drugs Market is Projected to Grow at a Healthy CAGR till 2025

The global Kidney Cancer Drugs Market is expected to grow at a healthy rate during the forecast period. Renal Cell Carcinoma (RCC) is one of the most common types of urologic tumors in adults. It accounts for around 2% of all new cases of tumor in humans. However, clinical removal of the cancerous cells is vital for a total cure from the disease. Until last few decades, surgical removal of kidneys. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

Early diagnosis is vital when it comes to treatment of this disease. Various treatment methods such as immune modulation therapy, Vascular Endothelial Growth Factor (VEGF) inhibitors, and cytokine therapy are utilized to cure the tumor. Additionally, variety of drugs are available for the treatment of diseases like kidney cancer when identified at an early stage. Hence, governments and healthcare organizations are engaging in awareness drives for early detection. This factor is anticipated to bode well for market over the forecast period.

Prevalence of RCC is projected to increase in near future owing to factors such as rising obesity and number of smokers and reduced physical activities due to changing lifestyle. Symptoms of renal cancer are similar to several other kidney disorders, which make it difficult to get detected. This factor also reduces survival rate among patients who are mostly diagnosed with RCC during routine checkups for some other medical conditions.

Browse Details of Report @ https://www.hexaresearch.com/research-report/kidney-cancer-drugs-market

The global market is majorly driven by changing lifestyle of the global population. Predominance of lifestyle influenced diseases is one of the major driving factors. Excessive smoking and alcohol consumption lead to chronic diseases including different types of cancer. This factor is expected to fuel the market for kidney cancer medicine in the forthcoming years. Rising geriatric population prone to chronic diseases is projected to propel demand for these medicines in the years to come.

Preference for these drugs over targeted remedies is anticipated to bode well for growth of the global market over the forecast period. Also, availability of a limited number of approved drugs is one of the factors assisting product demand. Kidney cancer medicines are one of the life protracting treatment options available for patients suffering from advanced stage of metastatic tumor. Furthermore, occurrence of this disease is expected to be higher in developed countries compared to developing regions. This factor is expected to impel demand for these medicines from regions like North America and Europe.

However, high price of branded drugs is projected to hinder overall growth over the forecast period. As a result, generic medicine variants are preferred over their branded counterparts. This factor is anticipated to obstruct market development in the forthcoming years.

Primary branded medicines in the global kidney cancer drugs market include Nexavar (Sorafenib), Inlyta (Axitinib), Avastin (Bevacizumab), Votrient (Pazopanib), Afinitor (Everolimus), Sutent (Sunitinib), Torisel (Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). Sutent was one of the highly demanded medicine types in the past. However, drugs like Votrient are also anticipated to witness substantial demand over the forecast period. At present, most potential drugs are in phase II and III clinical trials. Medicines such as Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib are projected to be commercialized and launched in the years to come.

North America accounted for a prominent market share in the past. High prevalence of kidney cancer and other kidney diseases is the primary growth driver. Additionally, U.S. is the largest market for pharmaceuticals. This factor is anticipated to bode well for the growth of the regional demand for kidney cancer drugs. Asia Pacific is estimated to witness significant growth over the forecast period. Lower cost of drug production, high disease prevalence, and rising awareness among healthcare professionals as well as consumers are projected to drive regional growth in the forthcoming years.
The global market is highly consolidated and displays high competition among key participants. Major pharmaceutical giants in the market include Pfizer Inc.; Bayer Pharma AG; GlaxoSmithKline Plc; Hoffman-La Roche; and Novartis AG. Major companies are capitalizing heavily on research and development and adopting strategies like collaborations, new product launches, business expansions, and innovation to uphold their market share.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

 About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Medical Morphine Market is Driven by Increasing Morphine Consumption in the US

27 February 2019, The global Medical Morphine Market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively.

North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market.

In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts.

On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally.

Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-morphine-market

Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine.

Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of California San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies.

Hexa Research has segmented the global medical morphine market based on Route of Administration , Indication and region:

Segmentation by Route of Administration, 2014 - 2024 (USD Million)
• Oral
• Injectables
• Others

Segmentation by Indication, 2014 - 2024 (USD Million)
• Cancer
• Arthritis
• Others

Segmentation by Region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
    • India
• Rest of the World

Key players analyzed
• Mallinckrodt Pharmaceuticals
• Alcaliber S.A.
• Purdue Pharma L.P.
• Pfizer Inc.
• Johnson Matthey Fine Chemicals
• Sun Pharmaceutical Industries Ltd.
• Verve Health Care Ltd.
• Taj Pharmaceuticals Limited
• NORTHEAST PHARM
• MANUS AKTTEVA BIOPHARMA LLP

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com

Breast Imaging Equipment Market - Global Industry Size, Analysis and Trends

19 February 2019, The global Breast Imaging Equipment Market is expected to grow at a fast pace over the forecast period (from 2012 to 2020). Growing occurrences of chronic ailments such as breast cancer are anticipated to drive product demand. Breast imaging equipment helps capture images of breast tissues to diagnose breast cancer. Rising awareness along with rapid innovations in technology is expected to boost the market in the forthcoming years.

With continuous technological developments, breast imaging devices are becoming increasingly digitalized and efficient in disease diagnosis. Factors such as high screening costs, stringent regulatory approval, low medical reimbursement procedures, and insufficient screening expertise are likely to hinder industry growth. Computer-aided diagnosis is expected to gain popularity in the worldwide market over the forecast period. Developing countries such as China, India, South Korea, and Brazil possess considerable market potential on account of high outsourcing rate and medical tourism.

Browse Details of Report @ https://www.hexaresearch.com/research-report/breast-imaging-equipment-industry

The global Breast Imaging Equipment Market is divided into products and regions. Products include breast MRI, nuclear imaging, mammography, tomosynthesis, bioelectric images, breast ultrasound, and scintimammography. Mammography is an extensively used method for detecting breast cancer. It is also considered the standard technique for diagnosis and screening. It uses very low doses of X-ray to capture 2D images of human breasts and reduces the adverse effects after screening. The second most preferred method is breast ultrasound; used for breast cancer testing. This segment may grow at a healthy rate over the forecast period due to its effectiveness in identifying breast tumors & cancers by examining the stiffness in tissues. Breast MRI is also a very efficient method because it identifies probable anomalies by examining the densities of breast tissues.

Geographically the worldwide Breast Imaging Equipment Market is categorized into Europe, North America, Asia-Pacific (APAC), and RoW. North America was the leading regional market in 2013 in terms of revenue. This growth was attributed to the presence of high-end technology, high awareness levels about breast cancer diagnosis & treatment, and a rapidly growing female geriatric population.
Europe is the second largest regional industry. The region may exhibit substantial growth till 2020 due to an expanding target based population and high investments in sunk cost. APAC is also likely to grow rapidly on account of several healthcare reforms coupled with excellent government support. Some of the major companies in the global industry are Siemens Healthcare Corp.; Aurora Imaging Technologies Inc.; GE Healthcare Ltd.; and Dilon Technologies Inc. Most of these market players adopt various business strategies, such as acquisitions, joint venture, NDP, geographical expansions, etc. in order to thrive and prosper in the long run.

A new device has been developed for 3D breast imaging by expert researchers at Dilon Technologies (Department of Energy's Thomas Jefferson National Accelerator Facility) and at the University of Florida (Department of Biomedical Engineering). Utilized in conjunction with mammography, nuclear medicine-based imaging is presently being employed as a secondary screening tool. This is done in order to decrease the number of erroneous positive results in women that have dense breasts and are at a greater risk of developing breast cancer.

Related Category Reports @ https://www.hexaresearch.com/research-category/medical-imaging-industry

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com/

Breast Cancer Market - Global Industry Size, Share, Analysis Report, 2025

19 February 2019, The global Breast Cancer Market is anticipated to witness a significant growth over the forecast period on account of growing target population base across the globe, rising prevalence of the disease, unhealthy lifestyle, exposure to radiations, and lack of physical exercises. Moreover, increasing efforts taken by major organizations across various regions to increase awareness levels is estimated to drive the market. Rising investments in R&D by various government and private organizations for development of effective drugs and treatments is also projected to play a key role in the market growth.

For instance, CytoDyn Inc., a biotech firm developing humanized CCR5 monoclonal antibodies for several therapeutic indications, received FDA approval for its Investigation New Drug (IND) submission and is allowed to start a phase 1b/2 trial for metastatic Triple-Negative Breast Cancer (TNBC). This disease subtype is one of the leading causes of cancer deaths across the globe and it accounts for around 10 % of the overall cases. The firm has identified several trial sites and aims to dose a few patients and expects to have initial readout during the first quarter of 2019. Changes in the number of Circulating Tumor Cells (CTCs) will be assessed every 21 days throughout the trial.

Browse Details of Report @ https://www.hexaresearch.com/research-report/breast-cancer-market

Breast cancer is detected during a screening test or after the patient notices a lump, which is the most common physical sign. According to the World Health organization (WHO), every year, about 200,000 new cases of breast cancer are diagnosed globally and this number is likely to increase in future. Some of the major types of breast cancer are ductal carcinoma in situ (DCIS), Invasive Ductal Carcinoma (IDC), and lobular carcinoma. Invasive ductal carcinoma hold a major share in the market owing to growing prevalence of IDC, government support, and initiatives undertaken to increase awareness among patients. Furthermore, unmet clinical needs in treatment of IDC has compelled manufacturers to conduct rigorous R&D activities. Chemotherapy, targeted, surgery and radiation, hormone, and biologic therapies are some of the most popular treatments for the disease.

North America has emerged as the prominent region in the market on account of changing lifestyle, growing prevalence of the disease, and presence of leading companies in U.S. Europe is likely to emerge highly lucrative over the coming years as a result of increased healthcare expenditure and technological developments. Countries, including Germany, France, and U.K., are some of the key revenue-generating economies in Europe.

Asia pacific is also projected to witness a considerable growth over the next few years owing to rapidly developing healthcare infrastructure and rising consumer disposable income. Moreover, ongoing awareness programs about breast cancer and available treatments by governments in the emerging countries, such as China and India are estimated to foster the growth.

Companies are adopting several business strategies, such as novel product development, technological advancements, and M&A in order to strengthen their foothold in the industry. For example, FDA recently approved the Investigational New Drug (IND) application for Athenex’s oral form of Eribulin. It is an anticancer drug promoted by Eisai Company under the brand name Halaven and can effectively treat metastatic breast cancer and liposarcoma. The company is allowed to initiate clinical trial program, which is expected to start in the first half of 2019. Other targeted therapies introduced to treat breast cancer include Perjeta (pertuzumab) and Kadcyla (T-DM1), which is a human antibody-drug conjugate. Leading companies operating in the global breast cancer market include Pfizer, Inc.; Novartis AG; Apthera, Inc.; BioNumerik Pharmaceuticals, Inc.; Eli Lilly and Company; and Oncothyreon, Inc.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com